Search
Trimethadione
go.drugbank.com/drugs/DB00347ApprovedWithdrawnAn anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)
Zuranolone
go.drugbank.com/drugs/DB15490ApprovedInvestigational[A260776,A260786] Zuranolone was designed with a pharmacological profile of a neuroactive steroid in mind while also possessing a pharmacokinetics profile of an oral, once-daily dosing formulation. … Zuranolone is a neuroactive steroid that acts as a positive allosteric modulator of the GABA<sub>A</sub> receptors.
Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive ModulatorOnion
go.drugbank.com/drugs/DB10548ApprovedOnion allergenic extract is used in allergenic testing.
Mixtures: BARICUS 50 IU/%1/%10 JEL , 50 G, NOSKAR 100 MG/50 IU/10 MG / G, JEL 120 GEflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigationalin which the patient develops an infection during a period of significant neutropenia. … [L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer
Sevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigationalSevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain … [L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]
Umeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigationalCOPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than … [A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product.
Tafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigational[L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling. … leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL))[L15302] has made it a desirable target in the treatment these B-cell malignancies.
Romidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexClobazam
go.drugbank.com/drugs/DB00349ApprovedIllicitInvestigationalClobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. … [A521,A522] In October 21, 2011, the FDA approved clobazam as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in adults and children aged two years and older.
Categories: GABA-A Receptor AgonistsTerbutaline
go.drugbank.com/drugs/DB00871ApprovedInvestigational[A230328] It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.[L32088] … Terbutaline was first synthesized in 1966[A230333] and described in the literature in the late 1960s and early 1970s.
Products: บรองโคนิล (N), TERBUTALIN AL 2.5